Abstract:Abstract The immune system initiates robust immune responses to defend against invading pathogens or tumor cells and protect the body from damage, thus acting as a fortress of the body. However, excessive responses cause detrimental effects, such as inflammation and autoimmune diseases. To balance the immune responses and maintain immune homeostasis, there are immune checkpoints to terminate overwhelmed immune responses. Pathogens and tumor cells can also exploit immune checkpoint pathways to suppress immune responses, thus escaping immune surveillance. As a consequence, therapeutic antibodies that target immune checkpoints have made great breakthroughs, in particular for cancer treatment. While the overall efficacy of immune checkpoint blockade (ICB) is unsatisfactory since only a small group of patients benefited from ICB treatment. Hence, there is a strong need to search for other targets that improve the efficacy of ICB. Ubiquitination is a highly conserved process which participates in numerous biological activities, including innate and adaptive immunity. A growing body of evidence emphasizes the importance of ubiquitination and its reverse process, deubiquitination, on the regulation of immune responses, providing the rational of simultaneous targeting of immune checkpoints and ubiquitination/deubiquitination pathways to enhance the therapeutic efficacy. Our review will summarize the latest findings of ubiquitination/deubiquitination pathways for anti-tumor immunity, and discuss therapeutic significance of targeting ubiquitination/deubiquitination pathways in the future of immunotherapy.

Ubiquitin ligases and the immune response.

Immune regulation by ubiquitin conjugation.

Immune regulation by protein ubiquitination: roles of the E3 ligases VHL and Itch

The ubiquitin system in immune regulation.

Immunity by Ubiquitylation: a Reversible Process of Modification

Advance in Research on the Regulation of Innate Immune Response by Ubiquitination

Ubiquitin Signaling in Immune Responses

Immune Regulation by Ubiquitin Tagging As Checkpoint Code.

E3 ubiquitin ligases, the powerful modulator of innate antiviral immunity

Ubiquitin ligase enzymes and de-ubiquitinating enzymes regulate innate immunity in the TLR, NLR, RLR, and cGAS-STING pathways

The E3 Ubiquitin Ligase Itch in T Cell Activation, Differentiation, and Tolerance

Ubiquitination of Immune System and Cancer Therapy

The Role of Ubiquitination in Regulation of Innate Immune Signaling.

Regulation of Innate Antiviral Immunity by Protein Ubiquitination

Regulation of T Cell Differentiation and Function by Ubiquitin-Specific Proteases.

Regulation of T Helper Cell Differentiation by E3 Ubiquitin Ligases and Deubiquitinating Enzymes

The E2 ubiquitin-conjugating enzyme UbcH5c: an emerging target in cancer and immune disorders

Emerging roles of Lys63‐linked polyubiquitylation in immune responses

The Role of E3 Ubiquitin Ligases and Deubiquitinases in Inflammatory Bowel Disease: Friend or Foe?

Targeted Modulation of E3 Ligases Using Engineered Ubiquitin Variants.

Targeting the ubiquitination/deubiquitination process to regulate immune checkpoint pathways